Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsCreative Biolabs offers an extensive suite of sophisticated assays designed to provide our global clientele with a thorough understanding of the Fc binding characteristics of their promising antibody candidates with a specific emphasis on detailed analysis of interactions with FcγRIIa. Our comprehensive portfolio enables in-depth characterization of binding affinity, kinetics, and specificity, which is crucial for predicting in vivo efficacy and guiding the optimization of antibody therapeutics.
FcγRIIa (CD32a), a low-affinity single-chain FcγR that is stimulatory but expressed on a variety of leukocytes, directly signals through ITAMs to facilitate cell-specific functions such as ADCP in macrophages, respiratory burst in neutrophils, platelet activation, and antigen presentation in dendritic cells. It frequently functions in conjunction with other stimulatory FcγRs, such as FcγRIIIa. Most importantly, a histidine/arginine polymorphism at position 131 produces three allelic variations (HH/RR/HR) with different antibody Fc binding affinities, therefore stressing the need to address FcγRIIa genotypes when designing antibody treatments with immune effector mechanisms.
Fig.1 The FcγRIIa receptor's signaling pathway.1
To ensure a detailed comprehension of the interaction between your custom antibodies and FcγRIIa, we have developed an advanced and all-encompassing testing platform, utilizing our in-depth knowledge of Fc receptor biology. We adopt a collaborative methodology, initiating an in-depth consultation to identify your unique requirements and customize the assay design for maximum effectiveness. After thorough implementation using our cutting-edge technologies, you will obtain a detailed report that includes binding kinetics, affinity measurements, and, if relevant, polymorphism-specific analysis, all presented in a clear and concise manner. Throughout the process, our knowledgeable professionals offer committed assistance and specialized insights, guaranteeing dependable collaboration and the provision of accurate, high-caliber data to enhance your antibody development projects.
We provide a range of tailored methodologies to effectively address our clients' project needs, including but not limited to:
| Objective: | The study aims to measure the binding affinity of sample-1 with FcγRIIa/CD32a subtypes via the surface plasmon resonance method. | |||||||||||||||||||||||||||||||||
| Assay Format: |
Binding and fitting curves between samples with FcγRIIa/CD32a (R167): steady-state model; Binding and fitting curves between samples with FcγRIIa/CD32a (H167): steady-state model; |
|||||||||||||||||||||||||||||||||
| Results: |
Sample-1 binding to CD32a (R167) We employed the steady-state affinity model to analyze the binding of sample-1 to captured CD32a (R167) (as shown in Fig.2), yielding an affinity constant (KD) of 1.29 × 10-5 M. Sample-1 binding to CD32a (H167) We employed the steady-state affinity model to analyze the binding of sample-1 to captured CD32a (H167) (as shown in Fig.3), yielding an affinity constant (KD) of 4.98×10-6 M. |
|||||||||||||||||||||||||||||||||
|
Table 1 SPR result summary between sample-1 with FcγRIIa/CD32a subtypes. |
||||||||||||||||||||||||||||||||||
Leveraging clinical-grade reference antibodies as positive controls, our experienced scientists at Creative Biolabs excel at customizing FcγRIIa binding assays with optimized parameters to address your unique research questions. To gain deeper mechanistic insight into the in vivo potency of your lead antibodies, we recommend combining this assay with cell-based cytotoxicity assays like ADCC and ADCP, while emphasizing the importance of careful data interpretation due to potential discrepancies with in vivo conditions caused by competing endogenous IgGs. Furthermore, Creative Biolabs offers comprehensive Fc engineering services to modulate antibody Fc characteristics for enhanced interaction with FcγRs precisely.
Our preclinical research has benefited much from Creative Biolabs' FcγRIIa binding test service. Accurate and consistent data on the affinity and kinetics of our antibody candidate for both the H131 and R131 alleles gave important new perspectives on its possible effector activities. I valued the team's responsiveness as well as their perceptive direction throughout the process. Their given report was thorough, current, and understandable. Their ability to fit our particular antibody format and the clear information on the experiment settings and findings were appreciated.
For more details about our FcγRIIa binding assay, please contact us immediately.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
Fig.2 Binding and fitting curves between sample-1 with FcγRIIa/CD32a (R167) at different concentrations.
Fig.3 Binding and fitting curves between sample-1 with FcγRIIa/CD32a (H167) at different concentrations.